More than $400 billion in manufacturing investment commitments from pharmaceutical companies in 11 days. That was the initial industry response to President Donald Trump's April 2, 2026 executive order imposing 100% Section 232 tariffs on branded, patented pharmaceuticals and active pharmaceutical ingredients — the largest sectoral tariff action in US history, and a wager that economic pain on imported drugs can rebuild the domestic supply chain three decades of offshoring dismantled.
The order, published in the Federal Register on April 3, sets a 100% tariff rate on imported branded and patented drugs and their active pharmaceutical ingredients, with large manufacturers subject to the full rate from July 31, 2026, and smaller producers given until September 29. Differentiated rates apply to allied trading partners: the European Union, Japan, South Korea, and Switzerland face a pre-existing 15% tariff; the United Kingdom faces 10%. Companies that commit to building US manufacturing facilities receive a transitional 20% rate, rising to 100% by April 2, 2030.
The pharmaceutical supply chain's vulnerability has been documented since at least the FDA's 2019 report on foreign API dependence. China manufactures an estimated 80% of the APIs used in US generic drugs; India produces roughly 40% of all finished generic pharmaceuticals sold in the United States, according to a 2024 Congressional Research Service analysis. COVID-19 exposed the risk in real time when Indian export restrictions on certain compounds briefly disrupted hospital supply chains in 2020 — an episode Trump's April 2 executive order cited by name in its preamble.
